Celularity (CELU) SEC Filings: History & Chart

Celularity Inc.(CELU)

Biotechnology · Florham Park, NJ

$1.58-0.13 (-7.60%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Celularity Inc.

Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.

Florham Park, NJ

115 employees

www.celularity.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Joseph Hariri

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 29, 2026	Sep 29, 2026	View filing
10-Q	Sep 29, 2026	Sep 29, 2026	View filing
SC 13D/A	Sep 28, 2026	Sep 28, 2026	View filing
8-K	Sep 28, 2026	Sep 28, 2026	View filing
4	Sep 25, 2026	Sep 25, 2026	View filing
4	Sep 25, 2026	Sep 25, 2026	View filing
4	Sep 25, 2026	Sep 25, 2026	View filing
8-K	Sep 14, 2026	Sep 14, 2026	View filing
NT 10-Q	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 7, 2026	Aug 7, 2026	View filing
8-K	Jul 29, 2026	Jul 29, 2026	View filing
25-NSE	Jul 22, 2026	Jul 22, 2026	View filing
8-K	Jun 30, 2026	Jun 30, 2026	View filing
8-K	Jun 25, 2026	Jun 25, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 23, 2026	Jun 23, 2026	View filing
SC 13D/A	Jun 23, 2026	Jun 23, 2026	View filing
8-K	Jun 12, 2026	Jun 12, 2026	View filing
8-K	Jun 3, 2026	Jun 3, 2026	View filing
8-K	May 28, 2026	May 28, 2026	View filing
NT 10-Q	May 15, 2026	May 15, 2026	View filing
10-K	Apr 30, 2026	Apr 30, 2026	View filing
3	Apr 24, 2026	Apr 24, 2026	View filing
3	Apr 24, 2026	Apr 24, 2026	View filing
3	Apr 24, 2026	Apr 24, 2026	View filing
SC 13D/A	Apr 22, 2026	Apr 22, 2026	View filing
8-K	Apr 21, 2026	Apr 21, 2026	View filing
4	Apr 15, 2026	Apr 15, 2026	View filing
4	Apr 15, 2026	Apr 15, 2026	View filing

SEC Filings

Recent Filings